Since JAK1 is also involved in the signal transduction of other barrier-damaging cytokines, such as IL-6 and VEGF, targeting this pathway may be a novel approach for the management of macular oedema, particularly those who are resistant to anti-VEGF therapy. The gene discussed is VEGFA; the disease is macular retinal edema.